We actually have a lot of data on Ozempic and GLP-1s generally, going back to the first GLP-1 FDA approval in 2005:
• Exenatide - FDA approved in 2005
• Liraglutide / Saxenda - FDA approved in 2010
• Dulaglutide / Trulicity - FDA approved in 2014
• Semaglutide / Ozempic/Wegovy - FDA approved in 2017
• Tirzepatide / Mounjaro - FDA approved in 2022
Ozempic / Semaglutide was FDA approved in 2017, but clinical trials started in 2008. That was 16 years ago. Obviously it's always possible there are even longer term side effects we're unaware of, but generally if this class of drug caused large scale problems for kidneys, liver, etc, we'd likely know by now.
• Exenatide - FDA approved in 2005
• Liraglutide / Saxenda - FDA approved in 2010
• Dulaglutide / Trulicity - FDA approved in 2014
• Semaglutide / Ozempic/Wegovy - FDA approved in 2017
• Tirzepatide / Mounjaro - FDA approved in 2022
Ozempic / Semaglutide was FDA approved in 2017, but clinical trials started in 2008. That was 16 years ago. Obviously it's always possible there are even longer term side effects we're unaware of, but generally if this class of drug caused large scale problems for kidneys, liver, etc, we'd likely know by now.